Amneal Pharmaceuticals to Acquire Kashiv BioSciences: Strategic Expansion and Robust Q1 2026 Results

Key Highlights

• Amneal Pharmaceuticals (Nasdaq: AMRX) to acquire 100% of Kashiv BioSciences in a transaction valued at up to \$1.1 billion, including \$375 million in cash, \$375 million in equity at closing, and up to \$350 million in milestone and royalty-based payments.
• Transformative deal establishes Amneal as a fully integrated, global biosimilars leader.
• Acquisition timed ahead of an estimated \$300 billion+ global biologics loss-of-exclusivity (LOE) opportunity over the next decade, enabling the company to capitalize on a massive wave of market expansion.
• Highly synergistic transaction with expected financial benefits of \$400–\$500 million, minimal impact to leverage, and a clear path to deleveraging below 3x net leverage by 2028.
• Strong preliminary Q1 2026 financial results: Net income up 217% year-over-year, gross margin up 750 basis points, and significant increases in adjusted EBITDA and adjusted EPS.
• Revised upward guidance for FY2026 standalone performance, reflecting management’s confidence in continued growth and value creation.

Strategic Rationale & Transaction Details

Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences, LLC, a leading U.S.-based biosimilars developer and manufacturer with robust end-to-end capabilities. The acquisition consideration includes \$375 million in cash and \$375 million in equity at closing, with up to \$350 million in additional milestone and royalty-based payments, plus funding of operations through closing. The transaction is subject to shareholder and regulatory approvals and is expected to close in the second half of 2026.

Kashiv is one of the few U.S.-based companies with proven biosimilars development and manufacturing and a substantial pipeline. The deal is expected to immediately scale Amneal’s global biosimilars platform, positioning the company to lead in the projected \$300 billion+ global biologics LOE market over the next decade.

The combination enhances Amneal’s speed-to-market, enables parallel development and commercialization, and is expected to yield more than 12 commercial biosimilars and over 20 additional pipeline products by 2030. The financial structure is designed to be accretive, with Amneal expecting substantial synergies, elimination of future milestone and royalty obligations, and incremental tax and structural benefits.

Management Commentary

Chirag and Chintu Patel, Co-Founders and Co-CEOs of Amneal, emphasized the strategic and financial logic behind the acquisition: “With Kashiv, Amneal becomes a fully integrated global biosimilars leader at the forefront of the next wave of U.S. affordable medicines. This is a natural next step in our strategy to build a leading, diversified biopharmaceutical company, and we are confident it will drive accelerated growth and long-term value creation.”

Dr. Sandeep Athalye, CEO of Kashiv BioSciences, added: “We are thrilled to combine Kashiv’s highly complementary portfolio and capabilities with Amneal at this critical inflection point for the biosimilar market, particularly in the U.S.”

Financial Results: Q1 2026 Performance

• Consolidated net revenue: \$723 million (up 4% YoY)
• Net income: \$78 million (up from \$25 million, +217% YoY)
• Gross margin: 44.3% (up from 36.8%, +750bps YoY)
• Adjusted EBITDA: \$202 million (up 19% YoY)
• Diluted EPS: \$0.19 (up from \$0.04, +375% YoY)
• Adjusted diluted EPS: \$0.27 (up from \$0.21, +29% YoY)
• Affordable Medicines net revenue: \$423 million (+2% YoY)
• Specialty net revenue: \$133 million (+23% YoY)
• AvKARE net revenue: \$166 million (-4% YoY, due to portfolio shift to higher margin products)

Management highlighted strong performance across its specialty and affordable medicines portfolios, including key product launches (e.g., CREXONT^®, BREKIYA^® autoinjector) and robust specialty segment growth.

Updated FY2026 Guidance

These updates reflect management’s strong outlook for 2026, driven by ongoing momentum, anticipated biosimilar launches, and sustained performance across all business segments.

Balance Sheet & Leverage

• Gross debt as of March 31, 2026: \$2.69 billion
• Net debt: \$2.49 billion
• Gross leverage: 3.7x (down from 3.9x at year-end 2025)
• Net leverage: 3.5x (unchanged from year-end 2025)

The company expects a clear path to deleveraging, aiming for below 3x net leverage by 2028.

Implications for Shareholders

• This acquisition is highly transformative and potentially price-sensitive, as it positions Amneal to become a global leader in biosimilars at a pivotal time for the industry.
• The deal structure is weighted toward long-term value creation and is designed to be accretive with substantial synergies.
• The company’s robust Q1 2026 performance and raised guidance signal strong operational momentum and confidence from management.
• Shareholder and regulatory approvals are still required; the transaction is expected to close in the second half of 2026.
• There are risks associated with the transaction, including integration, regulatory, and market uncertainties, as highlighted in the company’s forward-looking statements.
• An investor call was held on April 22, 2026, and the previously scheduled May 1 earnings call was cancelled and rescheduled to this date.

About the Companies

Amneal Pharmaceuticals is a global biopharmaceutical leader with approximately 300 products across complex generics, specialty, and biosimilars, delivering more than 160 million prescriptions annually, mainly in the U.S. Its segments include Affordable Medicines, Specialty, and AvKARE distribution.

Kashiv BioSciences is a U.S.-headquartered, vertically integrated biopharma company with advanced biosimilar capabilities and operations in both the U.S. and India.

Investor Information

Amneal recommends investors and security holders review all related SEC filings and proxy materials once available, as they will contain important information regarding the acquisition.

Disclaimer

This article contains forward-looking statements based on management’s current expectations. Actual results may differ materially due to various risks and uncertainties, including but not limited to regulatory approvals, integration risks, market conditions, and other factors outlined in Amneal’s filings with the SEC. Investors should review all official filings and consult their financial advisors before making investment decisions. This article is for informational purposes only and does not constitute investment advice or an offer to buy/sell shares.

View Amneal Pharmaceuticals, Inc. Historical chart here